Bilateral breast cancer following augmentation mammaplasty with polyacrylamide hydrogel injection: A case report

Zhao,Yaning; Yuan,Na; Li,Kuanzhi; Geng,Yi; Zhou,Haiping; Wang,Hua; Hou,Jie; Zhang,Bin; Cai,Yuan; Zhao,Xinhan

doi:10.3892/ol.2015.3116

Bilateral breast cancer following augmentation mammaplasty with polyacrylamide hydrogel injection: A case report

Authors:
- Yaning Zhao
- Na Yuan
- Kuanzhi Li
- Yi Geng
- Haiping Zhou
- Hua Wang
- Jie Hou
- Bin Zhang
- Yuan Cai
- Xinhan Zhao
View Affiliations

Affiliations: Department of Medical Oncology, Baoji Municipal Central Hospital, Baoji, Shaanxi 721008, P.R. China, Department of Oncology, The First Affiliated Hospital, Medical School of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China
Published online on: April 14, 2015 https://doi.org/10.3892/ol.2015.3116
Pages: 2687-2693

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer occurring following injection with polyacrylamide hydrogel (PAMG) for augmentation mammaplasty is rare. The present study reports the case of a 43‑year‑old female presenting with bilateral breast cancer 10 years after augmentation mammaplasty with PAMG injection and no family history of breast cancer. A 5.5x6.0‑cm mass in the right breast with multiple intumescent axillary lymph nodes was revealed and a palpable mass of ~1.0 cm was identified in the outer upper quadrant of the left breast. Multiple smaller nodules were observed in the pulmonary field. Pathological examination revealed invasive lobular grade II carcinoma in both breasts with ER(+++), PR(+++), C-erbB2(-), Top-2(+), in the right breast and ER(++), PR(++), c-erb-B2(-), Top-2(+) in the left. Preoperative chemotherapy, modified radical bilateral mastectomy with axillary clearance, postoperative chemotherapy, and an oophorectomy were conducted, followed by treatment with Arimedex® until the present date A number of valuable insights can be garnered from this case. First, close follow‑up is required for female patients who receive an injection of PAMG for augmentation mammaplasty in order to achieve an early diagnosis and to intervene in any incidences of breast cancer. Second, the differential diagnosis of dual primary carcinoma versus metastatic breast cancer is important and may be aided by the use of molecular technology. Third, it remains difficult to determine gene expression values for the prediction of chemotherapy sensitivity. Thus, discrimination between primary and secondary carcinomas is the principle barrier for identifying an appropriate treatment strategy when a patient is diagnosed with bilateral breast cancer.

View Figures

View References

1	Stephens S: Final report on the safety assessment of polyacrylamide. J Am Coll Toxicol. 10:193–198. 1991. View Article : Google Scholar
2	Christenen LH, Breiting VB, Aasted A, et al: Long-term effects of polyacrylamide hydrogel on human breast tissue. Plast Reconstr Surg. 111:1883–90. 2003. View Article : Google Scholar : PubMed/NCBI
3	de Cassia Novaes W and Berg A: Experiences with a non-biodegradable hydrogel (Aquamid): A pilot study. Aesthetic Plast Surg. 27:376–81. 2003. View Article : Google Scholar : PubMed/NCBI
4	Lloyd AW, Faragher RG and Denyer SP: Ocular biomaterials and implants. Biomaterials. 22:769–72. 2001. View Article : Google Scholar : PubMed/NCBI
5	Lin J, Qian YL, Yang Q, et al: Clinical analysis of complications of polyacrylamide hydrogel injection for augmentation mammoplasty in 118 cases. Zhonghua Zheng Xing Wai Ke Za Zhi. 23:101–102. 2007.(In Chinese). PubMed/NCBI
6	Abdallah A, Wesemann A, Saklaoui O, et al: Breast-conserving treatment of breast cancer after augmentation with injected hydrophilic polyacrylamide gel and review of the literature. Gynakol Geburtshilfliche Rundsch. 49:35–38. 2009.(In German). View Article : Google Scholar : PubMed/NCBI
7	Cheng NX, Liu LG, Hui L, Chen YL and Xu SL: Breast cancer following augmentation mammaplasty with polyacrylamide hydrogel (PAAG) injection. Aesthetic Plast Surg. 33:563–569. 2009. View Article : Google Scholar : PubMed/NCBI
8	Liu L, Long M, Wang J, et al: Quantitative analysis of diffusion-weighted imaging for diagnosis of puerperal breast abscess after polyacrylamide hydrogel augmentation mammoplasty: compared with other conventional modalities. Aesthetic Plast Surg. Jan 1–2015.(Epub ahead of print). View Article : Google Scholar
9	Carmichael AR, Bendall S, Lockerbie L, Prescott R and Bates T.: The long-term outcome of synchronous bilateral breast cancer is worse than metachronous or unilateral tumours. Eur J Surg Oncol. 28:388–91. 2002. View Article : Google Scholar : PubMed/NCBI
10	Gollamudi SV, Gelman RS, Peiro G, et al: Breast conserving therapy for stage I–II synchronous bilateral breast carcinoma. Cancer. 79:1362–1369. 1997. View Article : Google Scholar : PubMed/NCBI
11	Johnston PG, Lenz HJ, Leichman CG, et al: Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res. 55:1407–1412. 1995.PubMed/NCBI
12	Kakimoto M, Uetake H, Osanai T, et al: Thymidylate synthase and dihydropyrimidine dehydrogenase gene expression in breast cancer predicts 5-FU sensitivity by a histocultural drug sensitivity test. Cancer Lett. 223:103–111. 2005. View Article : Google Scholar : PubMed/NCBI
13	Bepler G, Kusmartseva I, Sharma S, et al: RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol. 24:4731–4737. 2006. View Article : Google Scholar : PubMed/NCBI
14	Seve P and Dumontet C: Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol. 9:168–175. 2008. View Article : Google Scholar : PubMed/NCBI
15	Braybrooke JP, Levitt NC, Joel S, et al: Pharmacokinetic study of cisplatin and infusional etoposide phosphate in advanced breast cancer with correlation of response to topoisomerase IIalpha expression. Clin Cancer Res. 9:4682–4688. 2003.PubMed/NCBI
16	Brase JC, Schmidt M, Fischbach T, et al: ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction. Clin Cancer Res. 16:2391–2401. 2010. View Article : Google Scholar : PubMed/NCBI
17	Xi TF, Fan CX, Feng XM, Wan ZY, Wang CR and Chou LL: Cytotoxicity and altered c-myc gene expression by medical polyacrylamide hydrogel. J Biomed Mater Res A. 78:283–290. 2006. View Article : Google Scholar : PubMed/NCBI
18	Jobsen JJ, van der Palen J, Ong F and Meerwaldt JH: Synchronous, bilateral breast cancer: prognostic value and incidence. Breast. 12:83–88. 2003. View Article : Google Scholar : PubMed/NCBI
19	Matsuo K, Fukutomi T, Akashi-Tanaka S, Hasegawa T and Tsuda H: Histological grade, p53, HER2 and hormone receptor status of synchronous bilateral breast carcinoma. Breast Cancer. 9:127–133. 2002. View Article : Google Scholar : PubMed/NCBI
20	Tulusan AH, Ronay G, Egger H and Willgeroth F: A contribution to the natural history of breast cancer. V. Bilateral primary breast cancer: incidence, risks and diagnosis of simultaneous primary cancer in the opposite breast. Arch Gynecol. 237:85–91. 1985. View Article : Google Scholar : PubMed/NCBI
21	Burns PE, Dabbs K, May C, et al: Bilateral breast cancer in northern Alberta: risk factors and survival patterns. Can Med Assoc J. 130:881–886. 1984.PubMed/NCBI
22	Gollamudi SV, Gelman RS, Peiro G, et al: Breast-conserving therapy for stage I–II synchronous bilateral breast carcinoma. Cancer. 79:1362–1369. 1997. View Article : Google Scholar : PubMed/NCBI
23	Chaudary MA, Millis RR, Hoskins EO, et al: Bilateral primary breast cancer: a prospective study of disease incidence. Br J Surg. 71:711–714. 1984. View Article : Google Scholar : PubMed/NCBI
24	Pandis N, Teixeira MR, Gerdes AM, et al: Chromosome abnormalities in bilateral breast carcinomas. Cytogenetic evaluation of the clonal origin of multiple primary tumors. Cancer. 76:250–258. 1995. View Article : Google Scholar : PubMed/NCBI
25	Imyanitov EN, Suspitsin EN, Grigoriev MY, et al: Concordance of allelic imbalance profiles in synchronous and metachronous bilateral breast carcinomas. Int J Cancer. 100:557–564. 2002. View Article : Google Scholar : PubMed/NCBI
26	Saad RS, Denning KL, Finkelstein SD, et al: Diagnostic and prognostic utility of molecular markers in synchronous bilateral breast carcinoma. Mod Pathol. 21:1200–1207. 2008. View Article : Google Scholar : PubMed/NCBI
27	Coradini D, Oriana S, Mariani L, et al: Is steroid receptor profile in contralateral breast cancer a marker of independence of the corresponding primary tumour? Eur J Cancer. 34:825–830. 1998. View Article : Google Scholar : PubMed/NCBI
28	Intra M, Rotmensz N, Viale G, et al: Clinicopathologic characteristics of 143 patients with synchronous bilateral invasive breast carcinomas treated in a single institution. Cancer. 101:905–912. 2004. View Article : Google Scholar : PubMed/NCBI
29	Janschek E, Kandioler-Eckersberger D, Ludwig C, et al: Contralateral breast cancer: molecular differentiation between metastasis and second primary cancer. Breast Cancer Res Treat. 67:1–8. 2001. View Article : Google Scholar : PubMed/NCBI
30	Safal M, Lower EE, Hasselgren PO, et al: Bilateral synchronous breast cancer and HER-2/neu overexpression. Breast Cancer Res Treat. 72:195–201. 2002. View Article : Google Scholar : PubMed/NCBI
31	Seo MY, Rha SY, Yang SH, et al: The pattern of gene copy number changes in bilateral breast cancer surveyed by cDNA microarray-based comparative genomic hybridization. Int J Mol Med. 13:17–24. 2004.PubMed/NCBI
32	Agelopoulos K, Tidow N, Korsching E, et al: Molecular cytogenetic investigations of synchronous bilateral breast cancer. J Clin Pathol. 56:660–665. 2003. View Article : Google Scholar : PubMed/NCBI
33	Ferlini C, Raspaglio G, Cicchillitti L, et al: Looking at drug resistance mechanisms for microtubule interacting drugs: does TUBB3 work? Curr Cancer Drug Targets. 7:704–712. 2007. View Article : Google Scholar : PubMed/NCBI
34	Kaira K, Takahashi T, Murakami H, et al: The role of βIII-tubulin in non-small cell lung cancer patients treated by taxane-based chemotherapy. Int J Clin Oncol. 18:371–379. 2013. View Article : Google Scholar : PubMed/NCBI
35	Jain M, Zhang L, He M, Zhang YQ, Shen M and Kebebew E: TOP2A is overexpressed and is a therapeutic target for adrenocortical carcinoma. Endocr Relat Cancer. 20:361–370. 2013. View Article : Google Scholar : PubMed/NCBI